Thursday, September 20, 2012

TOBI podhaler approved in UK

TOBI Podhaler, the First Antibiotic Inhaler for the Suppression of Chronic Pseudomonas Aeruginosa in Cystic Fibrosis, Launches in the UK9/20/2011
  • A new dry powder form of the established antibiotic tobramycin is now available in a hand-held inhaler (Podhaler) for the suppression of chronic Pseudomonas aeruginosa (Pa) lung infection in adults, adolescents and children aged 6 years and older with cystic fibrosis.1
  • Data show that therapy with tobramycin inhalation powder significantly decreases treatment time; providing a 72% reduction in overall treatment time compared with nebulised TOBI (tobramycin nebuliser solution).2
  • Cystic fibrosis is a life-threatening genetic disease, which usually requires numerous and complex daily treatment regimens, creating a high treatment burden for people living with this condition.3

You can watch a youtube video of how quick and easy it is to use.

The US is waiting for the FDA approval.

The FDA panel voted 13-1 in favor of it, now it needs the FDA's approval.